** Shares of LTR Pharma LTP.AX fall as much as 8.6% to A$0.96, their lowest level since Aug. 12
** Aussie biotech firm gets binding commitments for A$25 mln private placementat A$0.92/shr, a 12.4% discount to last close
** Says funds to speed development, commercialisation of its SPONTAN nasal spray treatment for erectile dysfunction
** Trading vol of 915,000+ shares tops 30-day avg of ~632,000
** Stock has now surged ~190% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。